IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF BUPRENORPHINE
The present invention provides compositions, methods, and kits for treatment of opiate addiction and pain. The invention provides a biocompatible nonerodible polymeric device which releases buprenorphine continuously with generally linear release kinetics for extended periods of time. Buprenorphine is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with buprenorphine.
1 - 28 . (canceled)
29 . A method for treatment of pain, comprising administering at least one implantable device subcutaneously, said implantable device comprising buprenorphine and a biocompatible, nonerodible polymeric matrix, wherein said buprenorphine is encapsulated within said matrix,
wherein said at least one implantable devices continuously releases buprenorphine in vivo over a sustained period of time through pores that open to the surface of said matrix at a steady state rate of about 0.1 to about 5 mg per day.
30 . A method according to claim 29 , wherein said at least one implantable device comprises a multiplicity of individual implantable devices, and wherein the combination of said implantable devices continuously releases buprenorphine in vivo over a sustained period of time at a steady state rate of about 0.1 to about 5 mg per day.
31 . A method according to claim 29 , wherein each of said at least one implantable devices is subcutaneously implanted at a site selected from the group consisting of the upper arm, the back, and the abdomen.
32 . A method according to claim 29 , wherein each of said at least one implantable devices comprises EVA.
33 . A method according to claim 32 , wherein each of said at least one implantable devices comprises about 10 to about 85% buprenorphine.
34 . A method according to claim 29 , wherein said sustained period of time is at least about 3 months.
35 . (canceled)
36 . A kit for use in treatment of pain, comprising at least one implantable device comprising buprenorphine and a biocompatible, nonerodible polymeric matrix, wherein said buprenorphine is encapsulated within said matrix and wherein when said implantable device is subcutaneously implanted in a mammal, said buprenorphine is continuously released in vivo over a sustained period of time through pores that open to the surface of said matrix at a steady state rate of at least about 0.1 mg per day, and instructions for use.